Kemudin I.M.

Ceftriaxone, the active ingredient in Kemudin I.M., is a third‑generation cephalosporin presented as an injection for intramuscular use. It treats a range of serious bacterial infections in adults and children, including community‑acquired pneumonia, meningitis, gonorrhea, urinary tract infections, skin and soft‑tissue infections, and intra‑abdominal infections.

GNH USA supplies Kemudin I.M. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ceftriaxone is a broad‑spectrum third‑generation cephalosporin used to treat infections caused by susceptible bacteria. - Community‑acquired pneumonia: provides rapid bacterial eradication and clinical improvement. - Meningitis: achieves high cerebrospinal fluid concentrations to treat bacterial meningitis. - Gonorrhea: eliminates Neisseria gonorrhoeae, preventing complications. - Urinary tract infections: resolves infection caused by Gram‑negative organisms. - Skin and soft tissue infections: clears cellulitis and wound infections. - Intra‑abdominal infections: treats polymicrobial infections within the abdominal cavity.

Ceftriaxone may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site pain: mild discomfort or tenderness at the intramuscular site. - Diarrhea: loose stools, often self‑limiting. - Nausea: occasional feeling of queasiness. - Rash: mild skin erythema or urticaria. - Elevated liver enzymes: transient increase in hepatic transaminases.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with respiratory distress and hypotension. - Clostridioides difficile colitis: severe diarrhea due to intestinal flora disruption. - Hemolytic anemia: immune‑mediated destruction of red blood cells. - Stevens‑Johnson syndrome: severe mucocutaneous reaction. - Biliary sludge or pseudolithiasis: precipitation in gallbladder leading to abdominal pain.

When prescribing ceftriaxone, clinicians should consider several safety and handling precautions. - Renal impairment: adjust therapy and monitor renal function in patients with reduced kidney function. - Hepatic dysfunction: use cautiously and monitor liver enzymes in patients with liver disease. - Neonates and infants: avoid intramuscular use in neonates < 28 days due to risk of calcium precipitation. - Concomitant calcium‑containing solutions: do not mix with calcium salts to prevent precipitation. - Allergic history: assess for prior cephalosporin or penicillin hypersensitivity before administration. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Ceftriaxone can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Calcium‑containing IV solutions: risk of insoluble calcium‑ceftriaxone precipitate. - Warfarin: may enhance anticoagulant effect, increasing bleeding risk.

Moderate Interactions (Monitor Closely): - Aminoglycosides: concurrent use may increase nephrotoxicity. - Loop diuretics: may potentiate electrolyte disturbances. - Oral contraceptives: may reduce effectiveness, advise additional contraceptive measures. - Antacids containing aluminum or magnesium: may affect absorption if given orally, though ceftriaxone is administered by injection.